Uterine Cancer Study Act of 2025
- Bill Number
- S. 2285
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-07-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2025-12-05T22:52:31Z
AI-Generated Summary
Purpose
The Uterine Cancer Study Act of 2025 directs the Secretary of Health and Human Services (HHS) to investigate the potential link between chemical hair straighteners and uterine cancer, with a special emphasis on higher rates among women of color. The goal is to review existing research, assess risks across diverse groups, and evaluate the need for stricter safety testing on these products.
Key Provisions
- Study Requirements: HHS must conduct a study, in collaboration with the Commissioner of Food and Drugs (FDA) and the Director of the National Institutes of Health (NIH). The study will:
- Review key findings from prior research on hair straighteners and uterine cancer.
- Examine effects on women and others at risk from all racial and ethnic backgrounds.
- Break down results based on whether products contain dyes, coloring, bleach, highlights, or perms.
- Assess if the FDA should require additional safety testing for hair straightening product manufacturers.
- Timeline and Reporting:
- Within 45 days of enactment, HHS submits a detailed plan (methodology) for the study to the Senate Committee on Health, Education, Labor, and Pensions and the House Committee on Energy and Commerce.
- The study must begin within 180 days of enactment.
- A final report on the study's findings must be submitted to the same congressional committees within 2 years of enactment.
- Definitions:
- Hair straightener: Refers specifically to chemical-based products used to straighten hair.
- Secretary: The head of HHS, who oversees the study.
Significant Changes to Existing Law
This bill introduces a new federal mandate for a targeted health study, which does not amend or repeal any prior laws. It builds on existing FDA authority over cosmetics by prompting a review of potential regulatory enhancements, such as new testing requirements, but does not immediately impose them.
Potential Impacts
- Government Agencies: HHS, FDA, and NIH will allocate resources for the study, including coordination and reporting to Congress, potentially influencing future FDA regulations on personal care products.
- Citizens: Could raise awareness of health risks from hair straighteners, especially for women of color who may face higher uterine cancer rates. If the study leads to stricter testing, it might result in safer products and better protection for users across all backgrounds.
- International Relations: No direct impacts, as the bill focuses on domestic health research and U.S. product regulation.
Main Stakeholders Affected
- Women of Color and At-Risk Individuals: Primary focus group due to noted higher cancer incidence; broader implications for all users of chemical hair products.
- Hair Product Manufacturers: May face potential new testing obligations if recommended by the study.
- Health Agencies: HHS, FDA, and NIH, responsible for executing the study.
- Congressional Committees: Senate Health, Education, Labor, and Pensions Committee and House Energy and Commerce Committee, which oversee the process and receive reports.
- Public Health Advocates: Groups addressing racial health disparities and consumer safety.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens FDA's role in cosmetic safety oversight without immediate rulemaking; any future testing requirements would follow standard administrative processes, potentially subject to legal challenges from industry if deemed overly burdensome.
- Constitutional: Aligns with Congress's authority to direct federal agencies on public health matters; no apparent conflicts with individual rights.
- Political: Highlights health inequities affecting marginalized communities, potentially advancing discussions on racial disparities in cancer research and product regulation; could influence broader cosmetic industry policies if findings prompt action.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Blunt Rochester, Lisa [D-DE]
Cosponsors (2)
Sen. Alsobrooks, Angela D. [D-MD], Sen. Booker, Cory A. [D-NJ]
Recent Actions
- 2025-07-15: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-07-15: Introduced in Senate
Bill Versions
- Uterine Cancer Study Act of 2025 — issued 2025-07-15 — PDF (3 pages)